BILHI Genetics

bilhigenetics.com

Bilhi Genetics is a biotech company at the edge of biotechnology and digital technologies. We ambition to become a major player of the personalized and predictive medicine. We are a start-up benefiting from more than 30 years of research in the field of genomics. More specifically the company aims at bringing new solutions to practitioners involved in curing pathologies causing severe fibrosis evolving into cancers, myocardial infarction, skin scars, kidney failure.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

WILLOW BIOSCIENCES EXPANDS ITS PORTFOLIO WITH A NEW PARTNERED PHARMACEUTICAL PROJECT

Willow Biosciences | June 01, 2022

news image

Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable ingredients is pleased to announce today that is has been engaged by a specialty pharmaceutical company (the "Counterparty") to optimize an enzyme vital to the development of a large volume Active Pharmaceutical Ingredient (API) used in nutraceutical and pharmaceu...

Read More

INOVIO REPORTS FDA PARTIAL CLINICAL HOLD FOR PLANNED PHASE 2 / 3 TRIAL OF COVID-19 VACCINE CANDIDATE INO-4800

INOVIO | September 28, 2020

news image

INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, announced that the U.S. Food and Drug Administration (FDA) has notified the company it has additional questions about the company's planned Phase 2/3 trial of its COVID-19 vaccine candidate INO-4800, including its CELLECTRA® 2000 delivery device to be used in the trial. Until the FDA's questions have been satisfac...

Read More

INDUSTRIAL IMPACT

RESILIENCE PARTNERS WITH A MAJOR PHARMACEUTICAL COMPANY FOR STRATEGIC BIOMANUFACTURING

Resilience | February 20, 2023

news image

National Resilience, Inc. (Resilience), a manufacturing company with a technology-focused mission to improve access to complex medications, recently announced a 10-year biomanufacturing partnership with a top pharmaceutical company for its portfolio of services in process and analytical development, drug substance manufacturing, and drug product manufacturing. The extensive agreement covers prospective biologic, vaccine, nucleic acid, cell, and gene therapy manufacturing. Resili...

Read More

INDUSTRIAL IMPACT

ENVERIC BIOSCIENCES ADVANCES DRUG DEVELOPMENT FOR MENTAL HEALTH INDICATIONS AND INTELLECTUAL PROPERTY PORTFOLIO

Enveric Biosciences, Inc | July 14, 2022

news image

Enveric Biosciences, Inc. a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today revealed drug discovery and development progress targeting mental health indications and intellectual property advances achieved during the first half of 2022. “The first half of 2022 was foundationally successful for Enveric. We validated and executed on the corporate premise that we can deploy Psy...

Read More
news image

MEDICAL

WILLOW BIOSCIENCES EXPANDS ITS PORTFOLIO WITH A NEW PARTNERED PHARMACEUTICAL PROJECT

Willow Biosciences | June 01, 2022

Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable ingredients is pleased to announce today that is has been engaged by a specialty pharmaceutical company (the "Counterparty") to optimize an enzyme vital to the development of a large volume Active Pharmaceutical Ingredient (API) used in nutraceutical and pharmaceu...

Read More
news image

INOVIO REPORTS FDA PARTIAL CLINICAL HOLD FOR PLANNED PHASE 2 / 3 TRIAL OF COVID-19 VACCINE CANDIDATE INO-4800

INOVIO | September 28, 2020

INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, announced that the U.S. Food and Drug Administration (FDA) has notified the company it has additional questions about the company's planned Phase 2/3 trial of its COVID-19 vaccine candidate INO-4800, including its CELLECTRA® 2000 delivery device to be used in the trial. Until the FDA's questions have been satisfac...

Read More
news image

INDUSTRIAL IMPACT

RESILIENCE PARTNERS WITH A MAJOR PHARMACEUTICAL COMPANY FOR STRATEGIC BIOMANUFACTURING

Resilience | February 20, 2023

National Resilience, Inc. (Resilience), a manufacturing company with a technology-focused mission to improve access to complex medications, recently announced a 10-year biomanufacturing partnership with a top pharmaceutical company for its portfolio of services in process and analytical development, drug substance manufacturing, and drug product manufacturing. The extensive agreement covers prospective biologic, vaccine, nucleic acid, cell, and gene therapy manufacturing. Resili...

Read More
news image

INDUSTRIAL IMPACT

ENVERIC BIOSCIENCES ADVANCES DRUG DEVELOPMENT FOR MENTAL HEALTH INDICATIONS AND INTELLECTUAL PROPERTY PORTFOLIO

Enveric Biosciences, Inc | July 14, 2022

Enveric Biosciences, Inc. a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today revealed drug discovery and development progress targeting mental health indications and intellectual property advances achieved during the first half of 2022. “The first half of 2022 was foundationally successful for Enveric. We validated and executed on the corporate premise that we can deploy Psy...

Read More